Upon joining the study, you will be informed about the trial’s purpose and procedures. You will be asked to provide consent to participate.

You will undergo initial assessments to confirm eligibility, including blood tests to check your hepatitis B virus (HBV) levels and liver function.

If eligible, you will begin treatment with either bepirovirsen or a placebo. The medication is administered as a solution for injection under the skin.

The treatment will last for 24 weeks, with specific loading doses designed to help achieve a functional cure of chronic hepatitis B.

Throughout the treatment period, you will have regular visits to monitor your health and the effects of the medication. This includes blood tests to measure HBV levels and liver function.

You will be asked to report any side effects or changes in your health during these visits.

After completing the 24-week treatment, you will stop taking the medication. Your health will continue to be monitored to assess the long-term effects of the treatment.

The goal is to achieve a functional cure, meaning the virus is no longer active in your body without the need for ongoing medication.

You will have follow-up visits for 24 weeks after stopping the treatment. These visits will help determine if the treatment was successful in achieving a functional cure.

During this period, you will not receive any rescue medication unless necessary.